Seaport Therapeutics
About
What does Seaport Therapeutics do?
Seaport Therapeutics is a biotechnology company focused on developing novel therapeutics that restore gut lymphatic function. Their lead candidate, GlyphCele™, is the first oral therapeutic designed for this purpose and has received significant funding from ARPA-H to advance its development.
What is Seaport Therapeutics's revenue?
StartupHub estimates Seaport Therapeutics's annual revenue at $10.2M (range $5.3M to $28.2M, 68% confidence), based on comparable companies in the sector.
What is Seaport Therapeutics's valuation?
StartupHub estimates Seaport Therapeutics's effective valuation at $1.1B (range $751.1M to $1.4B, 41% confidence), based on comparable companies in the sector.
How much funding has Seaport Therapeutics raised?
Seaport Therapeutics has raised a total of $340M in funding. The most recent round on record is Unknown.
Where is Seaport Therapeutics headquartered?
Seaport Therapeutics is headquartered in Cambridge, Massachusetts, USA.
When was Seaport Therapeutics founded?
Seaport Therapeutics was founded in 2021.
What industry does Seaport Therapeutics operate in?
Seaport Therapeutics operates in Biotechnology, Pharmaceuticals, HealthTech.
How many employees does Seaport Therapeutics have?
Seaport Therapeutics has approximately 64 people on record.
No comments yet. Be the first to share your take.